JP2010527593A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010527593A5 JP2010527593A5 JP2010508676A JP2010508676A JP2010527593A5 JP 2010527593 A5 JP2010527593 A5 JP 2010527593A5 JP 2010508676 A JP2010508676 A JP 2010508676A JP 2010508676 A JP2010508676 A JP 2010508676A JP 2010527593 A5 JP2010527593 A5 JP 2010527593A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- reovirus
- expression
- sigma
- mutation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000702263 Reovirus sp. Species 0.000 claims 39
- 229920001184 polypeptide Polymers 0.000 claims 38
- 108090000765 processed proteins & peptides Proteins 0.000 claims 38
- 102000004196 processed proteins & peptides Human genes 0.000 claims 38
- 230000035772 mutation Effects 0.000 claims 21
- 108020004707 nucleic acids Proteins 0.000 claims 7
- 102000039446 nucleic acids Human genes 0.000 claims 7
- 150000007523 nucleic acids Chemical class 0.000 claims 7
- 238000000034 method Methods 0.000 claims 4
- 208000015181 infectious disease Diseases 0.000 claims 3
- 230000002458 infectious effect Effects 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 239000002245 particle Substances 0.000 claims 3
- 101150080963 S4 gene Proteins 0.000 claims 2
- 210000000234 capsid Anatomy 0.000 claims 2
- 230000037430 deletion Effects 0.000 claims 2
- 238000012217 deletion Methods 0.000 claims 2
- 230000037431 insertion Effects 0.000 claims 2
- 238000003780 insertion Methods 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229940125721 immunosuppressive agent Drugs 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 238000002650 immunosuppressive therapy Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US93925507P | 2007-05-21 | 2007-05-21 | |
| PCT/CA2008/000964 WO2008141448A1 (en) | 2007-05-21 | 2008-05-21 | Mutant reoviruses and methods of making and using |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010527593A JP2010527593A (ja) | 2010-08-19 |
| JP2010527593A5 true JP2010527593A5 (enExample) | 2011-06-30 |
Family
ID=40031362
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010508676A Pending JP2010527593A (ja) | 2007-05-21 | 2008-05-21 | 変異レオウイルスならびにその作製および使用方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20080292594A1 (enExample) |
| EP (1) | EP2150613B1 (enExample) |
| JP (1) | JP2010527593A (enExample) |
| CN (2) | CN104195115A (enExample) |
| AR (1) | AR066649A1 (enExample) |
| AU (1) | AU2008253505B2 (enExample) |
| CA (1) | CA2680661C (enExample) |
| DK (1) | DK2150613T3 (enExample) |
| ES (1) | ES2611455T3 (enExample) |
| IL (1) | IL200690A (enExample) |
| MX (1) | MX2009012420A (enExample) |
| TW (1) | TW200909581A (enExample) |
| WO (1) | WO2008141448A1 (enExample) |
| ZA (1) | ZA200907017B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0720624D0 (en) * | 2007-10-20 | 2007-11-28 | Academisch Ziekenhuis Leiden | Viral Modification |
| EP2211880A4 (en) * | 2007-10-22 | 2012-11-14 | Oncolytics Biotech Inc | TREATMENT PROCEDURE FOR PROLIFERATIVE DISEASES |
| US8470312B2 (en) * | 2008-05-27 | 2013-06-25 | Oncolytics Biotech, Inc. | Abrogating proinflammatory cytokine production during oncolytic reovirus therapy |
| TW200951143A (en) * | 2008-05-27 | 2009-12-16 | Oncolytics Biotech Inc | Modulating interstitial pressure and oncolytic viral delivery and distribution |
| CN103269716B (zh) | 2010-12-02 | 2015-05-27 | 昂科利蒂克斯生物科技公司 | 冻干病毒制剂 |
| WO2012075379A2 (en) | 2010-12-02 | 2012-06-07 | Oncolytics Biotech Inc. | Liquid viral formulations |
| WO2015070323A1 (en) | 2013-11-15 | 2015-05-21 | Oncolytics Biotech Inc. | Oncolytic viruses and increased cancer treatment regimens |
| AU2017221592A1 (en) | 2016-02-16 | 2018-10-04 | Osaka University | Pharmaceutical composition for use in treating fibrosis |
| KR20210098202A (ko) * | 2020-01-31 | 2021-08-10 | 바이로큐어 주식회사 | 레오바이러스를 유효성분으로 포함하는 대장염의 예방 또는 치료용 조성물 |
| EP4268837A4 (en) * | 2020-12-22 | 2025-05-07 | Virocure, Inc. | NEW MODIFIED REOVIRUS AND ITS USE |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4554101A (en) * | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| US5023252A (en) * | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US6136307A (en) * | 1997-08-13 | 2000-10-24 | Oncolytics Biotech Inc. | Reovirus for the treatment of cellular proliferative disorders |
| US6110461A (en) * | 1997-08-13 | 2000-08-29 | Oncolytics Biotech Inc. | Reovirus for the treatment of neoplasia |
| US6565831B1 (en) * | 1999-02-24 | 2003-05-20 | Oncolytics Biotech Inc. | Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders |
| ES2301241T3 (es) * | 1998-06-12 | 2008-06-16 | Mount Sinai School Of Medicine Of The City University Of New York | Virus de influenza a atenuados, y composiciones inmunogenicas y formulaciones de vacunas que los contienen. |
| TWI289158B (en) * | 2000-08-10 | 2007-11-01 | Oncolytics Biotech Inc | Method of producing infectious reovirus |
| DK2189162T3 (da) * | 2000-11-09 | 2014-02-03 | Oncolytics Biotech Inc | Fremgangsmåder til behandling af cellulære proliferative forstyrrelser |
| DK2253701T3 (da) * | 2001-03-16 | 2014-10-20 | Oncolytics Biotech Inc | Fremgangsmåde til ekstraktion af en virus fra en cellekultur |
| US7163678B2 (en) * | 2002-11-07 | 2007-01-16 | Oncolytics Biotech Inc. | Reovirus for the treatment of ral-mediated cellular proliferative disorders |
| WO2005111200A1 (en) * | 2004-05-17 | 2005-11-24 | Universite De Montreal | Novel strains of reoviruses and methods of uses thereof |
| WO2007099401A2 (en) * | 2005-08-01 | 2007-09-07 | University Technologies International, Inc. | Oncolytic attenuated reoviruses for treatment of proliferative disorders |
-
2008
- 2008-05-20 AR ARP080102139A patent/AR066649A1/es unknown
- 2008-05-20 TW TW097118468A patent/TW200909581A/zh unknown
- 2008-05-21 US US12/124,522 patent/US20080292594A1/en not_active Abandoned
- 2008-05-21 MX MX2009012420A patent/MX2009012420A/es active IP Right Grant
- 2008-05-21 DK DK08748334.3T patent/DK2150613T3/en active
- 2008-05-21 JP JP2010508676A patent/JP2010527593A/ja active Pending
- 2008-05-21 CN CN201410339446.7A patent/CN104195115A/zh active Pending
- 2008-05-21 CN CN200880016669A patent/CN101679953A/zh active Pending
- 2008-05-21 EP EP08748334.3A patent/EP2150613B1/en active Active
- 2008-05-21 AU AU2008253505A patent/AU2008253505B2/en active Active
- 2008-05-21 WO PCT/CA2008/000964 patent/WO2008141448A1/en not_active Ceased
- 2008-05-21 CA CA2680661A patent/CA2680661C/en active Active
- 2008-05-21 ES ES08748334.3T patent/ES2611455T3/es active Active
-
2009
- 2009-09-02 IL IL200690A patent/IL200690A/en active IP Right Grant
- 2009-10-08 ZA ZA2009/07017A patent/ZA200907017B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Han et al. | Engineering the PRRS virus genome: updates and perspectives | |
| JP2014532691A5 (enExample) | ||
| Le Nouën et al. | Attenuation of human respiratory viruses by synonymous genome recoding | |
| CN105025922B (zh) | 包含硅化病毒的免疫原性组合物及其使用方法 | |
| JP2016513115A5 (enExample) | ||
| Okoli et al. | CRISPR/Cas9—advancing orthopoxvirus genome editing for vaccine and vector development | |
| He et al. | Coxsackievirus B3 engineered to contain microRNA targets for muscle-specific microRNAs displays attenuated cardiotropic virulence in mice | |
| Sherry et al. | Comparative molecular biology approaches for the production of poliovirus virus-like particles using Pichia pastoris | |
| CN111511397A (zh) | 具有密码子对去优化区域的重组病毒及其用于治疗癌症的用途 | |
| EP2978850B1 (en) | Enhanced expression of rna vectors | |
| Wang et al. | Research advances in replication-deficient viral vector vaccines | |
| WO2024012483A1 (zh) | 一种基因缺失的减毒非洲猪瘟病毒毒株及其构建方法和应用 | |
| CN116286685A (zh) | 一种基于CRISPR-Cas9技术的表达H9N2禽流感病毒XZ491毒株HA蛋白的重组血清4型禽腺病毒及其制备方法 | |
| CN106754922A (zh) | 调控自身增殖的轮状病毒编码的小rna分子 | |
| KR101384513B1 (ko) | 감염력이 있는 구제역바이러스 Ｏ형 ｃＤＮＡ 클론 및 클론의 전체염기서열 | |
| Hosen et al. | Adaptive Evolution of Dengue Virus: Interplay Between Viral Genetics and Host Immunity | |
| CN116676274B (zh) | 可自失活噬菌体及其制备方法和应用 | |
| KR102899731B1 (ko) | 캡시드 단위로 캡슐화된 핵산 오리가미 구조 | |
| JP2007516721A5 (enExample) | ||
| JP2019068814A5 (enExample) | ||
| ES2551380T3 (es) | Cepa atenuada de Myxoma virus para la utilización como medicamento oncolítico | |
| CN104593336A (zh) | 猪繁殖与呼吸综合征嵌合病毒RvHBJX及其应用 | |
| JP5306943B2 (ja) | 弱毒ウイルスの作出方法 | |
| JP2023537643A (ja) | 突然変異型オルフウイルス及びその使用 | |
| Israelsson et al. | Improved replication efficiency of echovirus 5 after transfection of colon cancer cells using an authentic 5’RNA genome end methodology |